<DOC>
	<DOCNO>NCT01482611</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability plasma pharmacokinetics ( PK ) JNJ-47910382 increase single oral dos ( take food ) 10 mg 600 mg maximum tolerate dose dose yield JNJ-47910382 plasma level approach predefined maximum mean exposure ( whichever come first ) healthy Caucasian Japanese participant . The foreseen maximum dose 600 mg . In addition , effect fasting ( ie JNJ-47910382 take without food ) plasma pharmacokinetics JNJ-47910382 one select oral dose give healthy Caucasian participant study . JNJ-47910382 drug develop treat Hepatitis C infection inhibitor reproduction machinery Hepatitis C virus ( HCV ) . Pharmacokinetics ( PK ) mean drug absorb bloodstream , distribute body eliminate body .</brief_summary>
	<brief_title>A Study Healthy Participants Investigating Safety , Tolerability Plasma Pharmacokinetics ( PK ) Single Oral Doses JNJ-47910382</brief_title>
	<detailed_description>This Phase I , single-center , first-in-human , double-blind ( neither participant investigator/medical staff know whether placebo JNJ-47910382 give certain moment ) , randomize ( treatment placebo JNJ-47910382 assign chance ) , placebo-controlled trial 18 healthy Caucasian 16 healthy Japanese participant investigate safety , tolerability plasma pharmacokinetics single oral dos JNJ-47910382 . This trial consist 3 Parts : 1. single dose escalation part healthy male female Caucasians , 2. single dose study investigate effect fast healthy male female Caucasians 3. single dose escalation part healthy male Japanese participant . Part 1 hold 6 session , test another dose JNJ-47910382 . Part 2 hold 1 session test one dose Part 3 hold 3 session , test another dose JNJ-47910382 . The dos pre-defined Caucasian cohort Part 1 10 mg , 30 mg , 75 mg , 150 mg , 300 mg , 600 mg , give Session I till include Session VI , respectively . These dos may adjust base result obtain previous session , exceed 600 mg , predefined maximal tolerate dose dose yield JNJ-47910382 plasma level approach predefined maximum mean exposure . The foreseen maximum dose 600 mg.The dos Japanese cohort , give Session VIII till include Session X , respectively , dose fasting-session ( Session VII ) define conduct study , base safety , tolerability PK profile obtain previously complete session . The Caucasian cohort divide 2 panel ( Panel 1 2 ) 9 participant , Panel , 3 different dos assign , respect washout period least 10 day . The Japanese cohort divide 2 panel ( Panel 3 4 ) 8 participant Panel 3 , 2 different dos assign , respect washout period least 10 day , Panel 4 1 dose JNJ-47910382 assign . Either Panel 1 2 select fasting-study Session , depend dose select fasting-study . Both , JNJ-47910382 placebo liquid administer mouth participant via oral dispenser . The decision escalate next dose Part 1 3 take caution . After session , safety tolerability ( till include 96h post dose ) PK ( till include 24h post dose ) result evaluate sponsor principle investigator - blinded fashion . Only case previous dose show generally safe tolerable maximum tolerate dose maximal mean plasma JNJ-47910382 level reach PK profile satisfactory , next session start , use select agree dose . Safety evaluation session include adverse event , vital sign ( blood pressure heart rate ) , electrocardiogram ( ECG ) ( evaluation activity heart certain time point ) , heart telemetry ( continuous evaluation activity heart , 12 hour ) , physical examination clinical laboratory test . Throughout trial , session , plasma PK profile JNJ-47910382 determine 96 hour dose . Also amount JNJ-47910382 recover urine determine 72 hour intake study medication Session IV Japanese Session dose ( either Session VIII , IX X ) . A blood sample dedicate analysis specific gene involve PK ( metabolism ) transport JNJ-47910382 collect participant , preferentially Day-2 one session . Also safety tolerability JNJ-47910382 determine throughout trial . In session triplicate ECG take , vital sign record , urinalysis perform biochemical blood parameter assess Days 1 , 2 4 . On Day3 , vital sign record triplicate ECG take . On Day-1 , triplicate ECG take . Heart telemetric recording perform Day-1 Day1 12 hour . Physical examination occur Day-1 Day5 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>Caucasian subject 18 45 year age , inclusive . Japanese subject 20 45 year age , inclusive . MALE Japanese subject reside outside Japan 5 year whose parent maternal paternal grandparent Japanese A body weight 50 kg screen Nonsmoking least 3 month prior screen Female Caucasian , except postmenopausal least 2 year surgically sterile . Hepatitis A , B C infection Human Immunodeficiency Virus Type 1 ( HIV1 ) Human Immunodeficiency Virus Type 2 ( HIV2 ) infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>JNJ-47910382</keyword>
	<keyword>47910382HPC1001</keyword>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hep C</keyword>
	<keyword>Healthy participant</keyword>
	<keyword>Japanese</keyword>
	<keyword>Caucasians</keyword>
</DOC>